319 related articles for article (PubMed ID: 17156591)
41. A multicenter and open label clinical trial of zoledronic acid 4 mg in patients with hypercalcemia of malignancy.
Kawada K; Minami H; Okabe K; Watanabe T; Inoue K; Sawamura M; Yagi Y; Sasaki T; Takashima S
Jpn J Clin Oncol; 2005 Jan; 35(1):28-33. PubMed ID: 15681601
[TBL] [Abstract][Full Text] [Related]
42. Safety of long-term administration of bisphosphonates in elderly cancer patients.
Tralongo P; Repetto L; Di Mari A; Mauceri G; Bollina R; Ferrau' F; Conti G
Oncology; 2004; 67(2):112-6. PubMed ID: 15539914
[TBL] [Abstract][Full Text] [Related]
43. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
44. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer.
Dranitsaris G; Hsu T
Support Care Cancer; 1999 Jul; 7(4):271-9. PubMed ID: 10423054
[TBL] [Abstract][Full Text] [Related]
45. Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple myeloma patients (the ZMAX trial).
Berenson JR; Boccia R; Lopez T; Warsi GM; Argonza-Aviles E; Lake S; Ericson SG; Collins R
J Support Oncol; 2011; 9(1):32-40. PubMed ID: 21465735
[TBL] [Abstract][Full Text] [Related]
46. Zoledronic acid in myeloma: MRC Myeloma IX.
Rajkumar SV
Lancet; 2010 Dec; 376(9757):1965-6. PubMed ID: 21131042
[No Abstract] [Full Text] [Related]
47. Pamidronate in prevention of bone complications in metastatic breast cancer: a cost-effectiveness analysis.
Hillner BE; Weeks JC; Desch CE; Smith TJ
J Clin Oncol; 2000 Jan; 18(1):72-9. PubMed ID: 10623695
[TBL] [Abstract][Full Text] [Related]
48. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid.
Zuradelli M; Masci G; Biancofiore G; Gullo G; Scorsetti M; Navarria P; Tancioni F; Berlusconi M; Giordano L; Santoro A
Oncologist; 2009 May; 14(5):548-56. PubMed ID: 19411682
[TBL] [Abstract][Full Text] [Related]
49. Safety and convenience of a 15-minute infusion of zoledronic acid.
Berenson J; Hirschberg R
Oncologist; 2004; 9(3):319-29. PubMed ID: 15169987
[TBL] [Abstract][Full Text] [Related]
50. Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma.
Coyte PC; Dobrow MJ; Broadfield L
Pharmacoeconomics; 2001; 19(8):845-54. PubMed ID: 11596836
[TBL] [Abstract][Full Text] [Related]
51. Bisphosphonate infusions: patient preference, safety and clinic use.
Chern B; Joseph D; Joshua D; Pittman K; Richardson G; Schou M; Lowe S; Copeman M; De Abreu Lourenco R; Lynch K
Support Care Cancer; 2004 Jun; 12(6):463-6. PubMed ID: 15088136
[TBL] [Abstract][Full Text] [Related]
52. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease.
DesHarnais Castel L; Bajwa K; Markle JP; Timbie JW; Zacker C; Schulman KA
Support Care Cancer; 2001 Oct; 9(7):545-51. PubMed ID: 11680835
[TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
Doggrell SA
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
[TBL] [Abstract][Full Text] [Related]
54. Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial.
Gimsing P; Carlson K; Turesson I; Fayers P; Waage A; Vangsted A; Mylin A; Gluud C; Juliusson G; Gregersen H; Hjorth-Hansen H; Nesthus I; Dahl IM; Westin J; Nielsen JL; Knudsen LM; Ahlberg L; Hjorth M; Abildgaard N; Andersen NF; Linder O; Wisløff F
Lancet Oncol; 2010 Oct; 11(10):973-82. PubMed ID: 20863761
[TBL] [Abstract][Full Text] [Related]
55. Myeloma--the therapeutic challenge.
Berenson JR
Med Klin (Munich); 2000 Oct; 95 Suppl 2():19-21. PubMed ID: 11089383
[TBL] [Abstract][Full Text] [Related]
56. [Adriamycin (doxorubicin)].
Ogura M
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1331-8. PubMed ID: 11681238
[TBL] [Abstract][Full Text] [Related]
57. Economic analysis of conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer.
Schulman KA; Stadtmauer EA; Reed SD; Glick HA; Goldstein LJ; Pines JM; Jackman JA; Suzuki S; Styler MJ; Crilley PA; Klumpp TR; Mangan KF; Glick JH
Bone Marrow Transplant; 2003 Feb; 31(3):205-10. PubMed ID: 12621482
[TBL] [Abstract][Full Text] [Related]
58. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.
Weide R; Koppler H; Antras L; Smith M; Chang MP; Green J; Wintfeld N; Neary MP; Duh MS
J Cancer Res Ther; 2010; 6(1):31-5. PubMed ID: 20479544
[TBL] [Abstract][Full Text] [Related]
59. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
Palmieri C; Fullarton JR; Brown J
Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
[TBL] [Abstract][Full Text] [Related]
60. CALGB 78909: Phase III trial of intravenous zoledronic acid in the prevention of bone loss in localized breast cancer patients with chemotherapy-induced ovarian failure.
Clin Adv Hematol Oncol; 2005 Feb; 3(2):105-6. PubMed ID: 16166977
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
